The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK

Microbes and Infection

Volumn 5, Issue 2, 2003, Pages 73-84

  Tapia, Esther ^a   Pérez Jiménez, Eva ^a   López Fuertes, Laura ^a   Gonzalo, Rosa ^a   Gherardi, M Magdalena ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Cytokines; Leishmaniasis; Vaccinia virus vectors

Indexed keywords

ANTIGEN; CYTOKINE; DNA; INTERLEUKIN 12; INTERLEUKIN 18; PROTEIN; PROTEIN P 36; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; DNA VECTOR; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; VACCINATION; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; GENETIC VECTORS; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INTERLEUKIN-12; INTERLEUKIN-18; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; VACCINES, DNA; VACCINIA VIRUS;

ANIMALIA; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; VACCINIA VIRUS;

EID: 0037295526     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(02)00077-1     Document Type: Article

References (70)

1. Leishmania/HIV co-infection in south-western Europe 1990-1998: retrospective analysis of 965 cases. Geneve, WHO/LEISH/2000. 42:2000;1-12.
2. Berrahal F., Mary C., Roze M., Berenger A., Escoffier K., Lamouroux D., Dunan S. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am. J. Trop. Med. Hyg. 55:1996;273-277.
3. Solano-Gallego L., Llull J., Ramos G., Riera C., Arboix M., Alberola J., Ferrer L. The ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet. Parasitol. 90:2000;37-45.
4. Report on the consultative meeting on Leishmania HIV-coinfection. Geneve, WHO/LEISH/95. 1995;114.
5. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., Gately M.K., Louis J.A., Albert G. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1996;1553.
6. Reiner S.L., Locksley R.M. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:1995;151-177.
7. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity and exacerbation belongs to different T helper subsets and response to distinct parasite antigen. J. Exp. M. 168:1988;1675-1684.
8. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Ann. Rev. Immunol. 10:1992;385-409.
9. Mossman T.R., Cherwinsky H.M., Bond M.W., Gieldin M.A., Coffman R.L. Two types of mouse helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:1986;2348-2357.
10. Solbach W., Laskay T. The host response to Leishmania infection. Adv. Immunol. 74:2000;275-317.
11. Afonso L.C.C., Scharton T., Vieira L.Q., Wysocka M., Trichieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 263:1994;235-237.
12. Gonzalo R.M., Ramírez J.R., Rodríguez D., Gonzalez-Aseguinolaza G., Larraga V., Esteban M. Protective immune response against cutaneous leishmaniasis by prime-booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect. 3:2001;701-711.
13. Lauwerys B.R., Renault J.C., Houssiau F.A. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine. 11:1999;822-830.
14. Kohno K., Kataoka J., Ohtsuki T., Suemoto Y., Okamoto I., Usui M., Ikeda M., Kurimoto M. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1997;1541-1550.
15. Yoshimoto T., Ohkusu K., Okamura H., Nakanishi K. Induction of host resistance to Leishmania major by IL-12 and IL-18 in vivo. IL-12 treatment upregulates IL-18 receptor expression on T cells. FASEB J. 12:1998;A106.
16. Xu D., Liew F.Y. Genetic vaccination against leishmaniasis. Vaccine. 12:1994;1534-1536.
17. Rivier D., Bovay P., Shah R., Didisheim S., Mauel J. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol. 21:1999;461.
18. Champsi J., McMahon-Pratt D. Membrane glycoprotein M-2 protects against L. amazonensis infection. Infect. Immun. 56:1988;3272-3279.
19. Skeiky Y.A., Guderain J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M., Barad R., Trichieru G., Reed S.G. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and produce interleukin-12. J. Exp. M. 181:1995;1527.
20. Skeiky Y.A., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Campos-Neto A., Reed S.G. LeIF: a recombinant Leishmania protein that induces IL-12 mediated Th1 cytokine profile. J. Immunol. 161:1998;6171.
21. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:1998;3279.
22. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A.W., Reed S.G. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2002;2828-2836.
23. Soong L., Duboise S.M., Kima P., McMahon-Pratt D. Leishmania pifanoi amastigote antigens protects mice against cutaneous leishmaniasis. Infect. Immun. 63:1995;3559-3566.
24. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., Seder R.A. Vaccination with DNA encoding immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. M. 186:1997;1137-1147.
25. Mougneau E., Altare F., Walkil A.E. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
26. Maillard I., Launois P., Himmelrich H., Acha-Orbea H., Diggelmann H., Locksley R.M., Louis J.A. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Eur. J. Immunol. 31:2001;1288.
27. Gonzalo R.M., Del Real G., Ramírez J.R., Rodríguez D., Heljasvaara R., Lucas P., Larraga V., Esteban M. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum p36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine. 20:2002;1226.
28. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:1996;421-423.
29. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 100:2001;87-103.
30. Caver T.E., Lockey T.D., Srinivas R.V., Webster R.G., Hurwitz J.L. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine. 17:1999;1567-1572.
31. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V.S., Smith G.L., McMichael A.J. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regimen. Vaccine. 16:1998;439-445.
32. Hanke T., McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66:1999;177-181.
33. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., McMichael A.J. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitotic gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
34. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188.
35. Robinson H.L., Montefiori D., Johnson P., Manson K.H., Kalish M.L., Lifson J., Rizvi T.A., Lu S., Hu S., Mazzara G., Panicali D.L., Herndon J.G., Glickman R., Candido M.A., Lydy S., Wyand M.S., McClure H.M. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant Pox virus booster immunizations. Nat. M. 5:1999;526-534.
36. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA. 95:1998;7648-7653.
37. Estcowt M.J., Ramsay A.J., Brooks A., Thomson S.A., Medvekzy C.J., Ramshaw I.A. Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int. Immunol. 14:2002;31-37.
38. + T cells. Virology. 280:2001;155-159.
39. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today. 21:2000;163-165.
40. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutin DNA vaccine. Vaccine. 15:1997;71-78.
41. Pardoll D.M., Beckerleg A.M. Exposing the immunology of naked DNA vaccines. Immunity. 3:1995;165-169.
42. Kim J.J., Bagarazzi M.L., Trivedi N., Hu Y., Kazahaya K., Wilson D.M., Ciccarelli R., Chattergoon M.A., Dang K., Mahalingam S., Chalian A.A., Agadjanyan M.G., Boyer J.D., Wang B., Weiner D.B. Engineering of in vivo immune responses to DNA immunization via co-delivery of costimulatory molecule genes. Nat. Biotechnol. 15:1997;641-646.
43. Paloetti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA. 93:1996;11349-11353.
44. McMahon-Pratt D., Rodríguez D., Rodríguez J.R., Zhang Y., Manson K., Bergman C., Rivas L., Rodríguez J.F., Lohman K.L., Ruddle N.H., Esteban M. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:1993;3351-3359.
45. + T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA. 90:1993;5214-5218.
46. Rodríguez J.F., Rodríguez D., Rodríguez J.R., McGowan E.B., Esteban M. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA. 85:1988;1667-1671.
47. González-Aseguinolaza G., Taladriz S., Marquet A., Larraga V. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur. J. Biochem. 259:1999;909-916.
48. Rodríguez D., Rodríguez J.R., Llorente M., Lucas P., Esteban M., Martinez A.C., Del Real G. Use of DNA priming and vaccinia virus boosting to trigger an efficient immune response to HIV-1 gp120. Gene Ther. Mol. Biol. 3:1999;179-187.
49. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 1985;3403-3409.
50. Sadick M.D., Locksley R.M., Tubbs C., Raff H.V. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J. Immunol. 136:1986;655-661.
51. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., Glaichenhaus N. Expression cloning of a protective Leishmania antigen. Science. 268:1995;563-566.
52. Gherardi M.M., Ramírez J.C., Rodríguez D., Rodríguez J.R., Sano G., Zavala F., Esteban M. IL-12 delivery from recombinant Vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 env in a dose-dependent manner. J. Immunol. 162:1999;6724-6743.
53. Gherardi M.M., Ramírez J.C., Esteban M. IL-12 enhancement of the cellular immune response against HIV-1 Env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose-dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J. Virol. 74:2000;6278-6286.
54. Reiner S.L., Zheng S., Wang Z.E., Stowting L., Lockslety R.M. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J. Exp. M. 179:1994;447-456.
55. Scott P., Eaton A., Gause W.C., di Zhou X., Hondowicz B. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84:1996;178-187.
56. Launois P., Swihart K.G., Milon G., Louis J.A. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J. Immunol. 158:1997;3317-3324.
57. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for the expansion of distinct helper T cell subsets. Proc. Natl. Acad. Sci. USA. 169:1989;59-72.
58. Heinzel F.P., Sadick M.D., Mutha S.S., Locksley R.M. Production of IFN-γ, interleukin 2, interleukin 4 and interleukin 10 by CD4 T lymphocytes in vivo during healing and progressive cutaneous leishmaniasis. Proc. Natl. Acad. Sci. USA. 88:1991;7011-7015.
59. Boom W.H., Liebster L., Abbas A.K., Titus R.G. Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution. Infect. Immun. 58:1990;3863-3870.
60. Wang Z.E., Reiner S.L., Hatam F., Heinzel F.P., Bouvier J., Turk C.W., Locksley R.M. Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151:1993;2077-2086.
61. Belding D.L. Textbook of Parasitology. 1965;217 Appleton-Century-Crofts, New York.
62. Finkelman F.D., Holmes J., Katona I.M. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 158:1990;816-826.
63. Deplazes P., Smith N.C., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2a antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 17:1995;451.
64. Gurunathan S., Stobie L., Prussin C., Sacks D.L., Glaichenhaus N., Fowell D.J., Locksley R.M., Chang J.T., Wu C., Seder R.A. Requirements for the maintenance of Th immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165:2000;915.
65. Rogers K.A., DeKrey G.K., Mbow M.L., Gillespie R.D., Brodskyn C.I., Titus R.G. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol. Lett. 209:2002;1-7.
66. Mountford A.P., Anderson S., Wilson R.A. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J. Immunol. 156:1996;4739.
67. Miller M.A., Skeen M.J., Ziegler H.K. Nonviable bacterial antigens administered with IL-12 generate antigen-specific T cell responses and protective immunity against Listeria monocytogenes. J. Immunol. 155:1995;4817.
68. Mahon B.P., Ryan M.S., Griffin F., Mills K.H.G. Interleukin 12 produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular Pertussis vaccine by promoting induction of Th1 cells. Infect. Immun. 64:1996;5295.
69. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T., Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation. Vaccine. 20:2002;2439-2447.
70. Chang J.T., Segal B.M., Nakanishi K., Okamura H., Shevach E.M. The costimulatory effect of IL-18 on the induction of antigen-specific IFN-γ production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor 2 subunit. Eur. J. Immunol. 30:2000;1113-1119.